Telomerase

• 

  Subject Areas on Research

  • A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro. 
  • A genetically tractable model of human glioma formation. 
  • A network of genetic events sufficient to convert normal human cells to a tumorigenic state. 
  • A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. 
  • A novel human cancer culture model for the study of prostate cancer. 
  • A novel neoplastic primary tumor-derived human prostate epithelial cell line. 
  • A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. 
  • A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. 
  • An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. 
  • Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. 
  • Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. 
  • C-terminal regions of the human telomerase catalytic subunit essential for in vivo enzyme activity. 
  • Characterization of interactions between PinX1 and human telomerase subunits hTERT and hTR. 
  • Chromosome end-to-end associations and telomerase activity during cancer progression in human cells after treatment with alpha-particles simulating radon progeny. 
  • Conditional telomerase induction causes proliferation of hair follicle stem cells. 
  • Creation of human tumour cells with defined genetic elements. 
  • Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. 
  • Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". 
  • Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. 
  • Extended passaging, but not aldehyde dehydrogenase activity, increases the chondrogenic potential of human adipose-derived adult stem cells. 
  • Genetic modeling of human rhabdomyosarcoma. 
  • Genetically engineered human cancer models utilizing mammalian transgene expression. 
  • Human arteries engineered in vitro. 
  • Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. 
  • In vivo regulation of hTERT expression and telomerase activity by androgen. 
  • In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells. 
  • Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. 
  • Influence of ATM function on telomere metabolism. 
  • Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. 
  • Interactions of TLC1 (which encodes the RNA subunit of telomerase), TEL1, and MEC1 in regulating telomere length in the yeast Saccharomyces cerevisiae. 
  • Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. 
  • Mammalian genes induce partially reprogrammed pluripotent stem cells in non-mammalian vertebrate and invertebrate species. 
  • Mechanism of apoptosis and determination of cellular fate in chromium(VI)-exposed populations of telomerase-immortalized human fibroblasts. 
  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. 
  • Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. 
  • Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. 
  • N-terminal domains of the human telomerase catalytic subunit required for enzyme activity in vivo. 
  • NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer-Initiating Cells. 
  • Novel human bronchial epithelial cell lines for cystic fibrosis research. 
  • Perifosine as a potential novel anti-telomerase therapy. 
  • Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. 
  • Putative telomere-recruiting domain in the catalytic subunit of human telomerase. 
  • Rapid telomere shortening in children. 
  • Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. 
  • Relevance and safety of telomerase for human tissue engineering. 
  • Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. 
  • Rescue of an hTERT mutant defective in telomere elongation by fusion with hPot1. 
  • Resistance to apoptosis, increased growth potential, and altered gene expression in cells that survived genotoxic hexavalent chromium [Cr(VI)] exposure. 
  • Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. 
  • Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma. 
  • Stretching the surface epithelium. 
  • TERC is not a major gene in human neural tube defects. 
  • TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. 
  • TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. 
  • TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. 
  • Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. 
  • Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. 
  • Telomerase reverse transcriptase is required for the localization of telomerase RNA to cajal bodies and telomeres in human cancer cells. 
  • Telomerase, cell immortality, and cancer. 
  • Telomere structure and maintenance gene variants and risk of five cancer types. 
  • Tethering telomeric double- and single-stranded DNA-binding proteins inhibits telomere elongation. 
  • The Rb-related p130 protein controls telomere lengthening through an interaction with a Rad50-interacting protein, RINT-1. 
  • The catalytic subunit of yeast telomerase. 
  • The detection of telomerase activity in patients with adenocarcinoma of the pancreas by fine needle aspiration. 
  • The nucleolar localization domain of the catalytic subunit of human telomerase. 
  • The roles of telomeres and telomerase in cell life span. 
  • The scaffold protein WRAP53β orchestrates the ubiquitin response critical for DNA double-strand break repair. 
  • Utility of telomerase-pot1 fusion protein in vascular tissue engineering. 
  • hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Linardic, Corinne Mary, Associate Professor of Pediatrics, Pharmacology & Cancer Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor in Community and Family Medicine, Duke Cancer Institute
  • Yan, Hai, Henry S. Friedman Professor of Neuro-Oncology in the School of Medicine, Pathology